HomeProductsBuilding BlocksFunctional GroupsCarboxylic AcidsEfaproxiral
Chemical structure of CAS 131179-95-8

Efaproxiral

CAS No.131179-95-8
MDL No.N/A
MFC20H23NO4
MW341.40
InChI KeyBNFRJXLZYUTIII-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.131179-95-8
Product NameEfaproxiral

Biological Targets

HBA1·HBA2·HBB

Associated Conditions

lung cancer·neoplasm·Central Nervous System Neoplasm·breast cancer
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats.

American journal of physiology. Heart and circulatory physiology • Vol. 282, Issue 5 • 2002
PMID: 11959653DOI: 10.1152/ajpheart.00863.2001

Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia.

American journal of physiology. Heart and circulatory physiology • Vol. 283, Issue 1 • 2002
PMID: 12063279DOI: 10.1152/ajpheart.01066.2001

Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 20, Issue 14 • 2002
PMID: 12118029DOI: 10.1200/JCO.2002.01.096

[Blood doping and cardiovascular consequences].

Presse medicale (Paris, France : 1983) • Vol. 31, Issue 40 • 2002
PMID: 12579085

Documentation